Compare JJSF & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JJSF | ORKA |
|---|---|---|
| Founded | 1971 | 2004 |
| Country | United States | United States |
| Employees | 1800 | N/A |
| Industry | Specialty Foods | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.6B |
| IPO Year | 1995 | N/A |
| Metric | JJSF | ORKA |
|---|---|---|
| Price | $84.19 | $66.44 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 12 |
| Target Price | ★ $140.00 | $92.50 |
| AVG Volume (30 Days) | 209.6K | ★ 2.1M |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | ★ 3.67% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $1,022,038,000.00 | N/A |
| Revenue This Year | $0.30 | N/A |
| Revenue Next Year | $1.70 | N/A |
| P/E Ratio | $1,744.80 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $73.75 | $8.91 |
| 52 Week High | $129.24 | $91.00 |
| Indicator | JJSF | ORKA |
|---|---|---|
| Relative Strength Index (RSI) | 53.40 | 56.53 |
| Support Level | $79.95 | $27.81 |
| Resistance Level | $87.73 | $91.00 |
| Average True Range (ATR) | 2.33 | 5.54 |
| MACD | 0.52 | -1.36 |
| Stochastic Oscillator | 51.89 | 18.18 |
J&J Snack Foods Corp. manufactures snack foods and distributes frozen beverages, which it markets nationally to the foodservice and retail supermarket industries. The company's portfolio of frozen beverages, frozen novelties, and baked goods includes soft pretzels, frozen juice treats and desserts, stuffed sandwiches, churros, funnel cakes, cookies, and other snack foods and drinks. It operates through three segments: Food Service, which sells snacks, desserts, and baked goods at the point of sale; Retail Supermarkets, which sells frozen and prepackaged products to supermarkets; and Frozen Beverages, which sells frozen beverages under the ICEE, Slush Puppie, and Parrot Ice brands in the United States, Mexico, and Canada. The majority of revenue comes from the Food Service segment.
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.